Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?Oghlakian GO; Sipahi I; Fang JCMayo Clin Proc 2011[Jun]; 86 (6): 531-9Heart failure with preserved ejection fraction (HF-PEF) is the clinical syndrome of heart failure associated with normal or near-normal systolic function. Because inhibition of the adrenergic and renin-angiotensin-aldosterone systems has been so effective in the treatment of systolic heart failure, these same therapies have been the subject of recent clinical trials of HF-PEF. In this review, we examine the current evidence about treatment of HF-PEF, with particular emphasis on reviewing the literature for large-scale randomized clinical studies. The lack of significant benefit with neurohormonal antagonism in HF-PEF suggests that this condition might not involve neurohormonal activation as a critical pathophysiologic mechanism. Perhaps heart failure as we traditionally think of it is the wrong paradigm to pursue as we try to understand this condition of volume overload known as HF-PEF.|*Exercise[MESH]|*Stroke Volume[MESH]|Adrenergic beta-Antagonists/therapeutic use[MESH]|Angiotensin II Type 1 Receptor Blockers/therapeutic use[MESH]|Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]|Benzimidazoles/therapeutic use[MESH]|Biphenyl Compounds/therapeutic use[MESH]|Calcium Channel Blockers/therapeutic use[MESH]|Cardiovascular Agents/pharmacology/*therapeutic use[MESH]|Digitalis Glycosides/therapeutic use[MESH]|Exercise Tolerance[MESH]|Heart Failure/*drug therapy/metabolism/pathology/*physiopathology/therapy[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use[MESH]|Hypertrophy, Left Ventricular/drug therapy/physiopathology[MESH]|Irbesartan[MESH]|Mineralocorticoid Receptor Antagonists[MESH]|Randomized Controlled Trials as Topic[MESH]|Renin-Angiotensin System/*drug effects[MESH]|Tetrazoles/therapeutic use[MESH]|Ventricular Dysfunction, Left/drug therapy/physiopathology[MESH]|Verapamil/therapeutic use[MESH] |
